After the declarations of intention to restore the health independence of France undermined during the pandemic, the passage to the act. During a visit on Friday morning to Villeneuve-la-Garenne (Hauts-de-Seine) in the workshops of the Seqens pharmaceutical laboratory, Emmanuel Macron announced two measures to try to relocate the production of drugs in France.
Read also: Relocation: paracetamol, the first practical case for labs
First, the drop in the price of drugs, in effect for ten years so as not to dig the hole in Social Security, will be more limited than usual in 2021. There will be a reduction in " the effort that is required. each year to drug companies of 300 million euros for the next financial plan ”, affirmed the President of the Republic. In other words, this contraction in tariffs, which is 900 million this year, will fall to around 600 million next year. " This will help restore the competitiveness of French drug companies, 75% of which have less than fifty employees», Estimates Frédéric Collet, president of Leem (The drug companies) and of the French subsidiary of the laboratory Novartis. Finding a little leeway, laboratories should be less tempted to have their products manufactured abroad.
Speed up the launch
Second decision of the executive, the procedures for marketing drugs will be simplified to accelerate their launch. “The reform of temporary authorizations for use on January 1 is a pillar of this 'France relaunch',” explains Emmanuel Macron. Very appreciated by manufacturers, this formula needed some grooming because, over time, it had become so complex that laboratories gave up using it. " This should strengthen the attractiveness of France to laboratories which, suddenly, will be able to more easily design new drugs and administer them to patients, " says Frédéric Collet. It is urgent: today, only 3% of the molecules developed by biotechs are manufactured in France.